|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
6
|
|
gptkbp:bfsParent
|
gptkb:Briviact
|
|
gptkbp:activities
|
S V2 A binding
|
|
gptkbp:approves
|
gptkb:2016
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Briviact
|
|
gptkbp:category
|
gptkb:unknown
gptkb:C
|
|
gptkbp:class
|
anticonvulsants
|
|
gptkbp:clinical_trial
|
Phase III
monotherapy
adjunctive therapy
|
|
gptkbp:contraindication
|
hypersensitivity
|
|
gptkbp:defines
|
UCB 34714
|
|
gptkbp:developed_by
|
gptkb:UCB_Pharma
|
|
gptkbp:dosage_form
|
oral tablet
oral solution
IV injection
|
|
gptkbp:duration
|
short-term
long-term
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Brivaracetam
|
|
gptkbp:indication
|
partial-onset seizures
|
|
gptkbp:ingredients
|
C11 H14 N2 O3
|
|
gptkbp:interacts_with
|
gptkb:beer
oral contraceptives
other antiepileptic drugs
|
|
gptkbp:is_atype_of
|
N03 A X20
|
|
gptkbp:is_available_on
|
gptkb:software_framework
gptkb:tablet
injection
|
|
gptkbp:is_used_for
|
gptkb:psychologist
|
|
gptkbp:lifespan
|
8 to 9 hours
|
|
gptkbp:manager
|
oral
intravenous
|
|
gptkbp:marketed_as
|
gptkb:Europe
gptkb:Australia
gptkb:Japan
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pharmacokinetics
|
linear pharmacokinetics
|
|
gptkbp:research_areas
|
clinical trials
neurology
pharmacology
|
|
gptkbp:side_effect
|
dizziness
fatigue
nausea
irritability
drowsiness
|
|
gptkbp:social_structure
|
pyrrolidine derivative
|
|
gptkbp:targets
|
synaptic vesicle protein 2 A
|
|
gptkbp:type_of
|
357336-20-0
|